Efstathia Giannopoulou

Efstathia Giannopoulou

Auto-generated profile, based on publicly available information

Efstathia Giannopoulou

Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Patras, Greece

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2011 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
DPDionysios J. Papachristou
Dionysios J. Papachristou
AKAngeliki Korpetinou
Angeliki Korpetinou
EGEfstathia Giannopoulou
Efstathia Giannopoulou
AAAnna G. Antonacopoulou
Anna G. Antonacopoulou
HPHelen Papadaki
Helen Papadaki
HKHaralabos P. Kalofonos
Haralabos P. Kalofonos

1 January 2012 in Vascular Cell
Verified
Journal Article
Open access
PDF file
MKMarina Koutsioumpa
Marina Koutsioumpa
GDGeorgia Drosou
Georgia Drosou
CMConstantinos M. Mikelis
Constantinos M. Mikelis
KTKaterina Theochari
Katerina Theochari
DVDionussios Vourtsis
Dionussios Vourtsis
EPEvangelia Papadimitriou
Evangelia Papadimitriou
Background Pleiotrophin (PTN) is a heparin-binding growth factor with significant role(s) in tumour growth and angiogenesis. Although implication of endogenous PTN has been studied in several in vivomodels of tumour angiogenesis, its role in physiological angiogenesis has not been addressed. In the present work, we studied expression and functional significance of endogenous PTN during angiogenesis in the chicken embryo chorioallantoic membrane (CAM). Methods Using molecular, cellular and biochemical assays, we studied the expression pattern of PTN in CAM and human endothelial cells and its possible interaction with nucleolin (NCL). CAM cells were transfected with a pCDNA3.1 vector, empty (PC) or containing full length cDNA for PTN in antisense orientation (AS-PTN). Angiogenesis was estimated by measuring total vessel length. In vitro, human endothelial cells migration was studied by using a transwell assay, and down-regulation of NCL was performed by using a proper siRNA. Results Endogenous PTN mRNA and protein levels, as well as protein levels of its receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) were maximal at early stages, when CAM angiogenesis is active. Application of AS-PTN onto CAM at days of active angiogenesis was not toxic to the tissue and led to dose-dependent decreased expression of endogenous PTN, ERK1/2 activity and angiogenesis. Interestingly, endogenous PTN was also immunolocalized at the endothelial cell nucleus, possibly through interaction with NCL, a protein that has a significant role in the nuclear translocation of many proteins. Down-regulation of NCL by siRNA in human endothelial cells significantly decreased nuclear PTN, verifying this hypothesis. Moreover, it led to abolishment of PTN-induced endothelial cell migration, suggesting, for the first time, that PTN-NCL interaction has a functional significance. Conclusions Expression of endogenous PTN correlates with and seems to be involved in angiogenesis of the chicken embryo CAM. Our data suggest that NCL may have a role, increasing the number of growth factors whose angiogenic/tumorigenic activities are mediated by NCL.

12 May 2009 in Oncology
Verified
Journal Article
Closed access
PDF file
Andreas A. ArgyriouAndreas A. Argyriou
Andreas A. Argyriou
EGEfstathia Giannopoulou
Efstathia Giannopoulou
HKHaralabos P. Kalofonos
Haralabos P. Kalofonos
Angiogenesis is considered to be a regulating factor of vascular development and growth for malignant gliomas, including glioblastoma multiforme (GBM) and anaplastic astrocytomas. The mechanism of angiogenesis is primarily mediated by hypoxia through chronic activation of the HIF pathway leading to the production of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor. Alternatively, it can be triggered by genetic factors. The VEGF/VEGFR-2 is the predominant angiogenic signalling pathway in malignant gliomas. Currently, anti-angiogenic molecularly targeted therapies, including administration of monoclonal antibodies or tyrosine kinase inhibitors (TKIs), are being increasingly adopted for treating GBMs. This approach is based on the ability of anti-VEGFRs monoclonal antibodies to decrease vascular permeability and perfusion, whereas the use of TKIs is mainly based on their capacity to interfere with cell communication, receptor signaling and growth of tumours. Our aim is to review current knowledge on angiogenesis as a molecular pathogenetic mechanism of malignant gliomas and to critically look at and discuss antiangiogenic molecularly targeted therapies for these brain malignancies. We also highlight areas of future research to pursue.

18 April 2007 in Clinical & Experimental Metastasis
Verified
Journal Article
Closed access
PDF file
VVVassilios Vassiliou
Vassilios Vassiliou
CKChristine Kalogeropoulou
Christine Kalogeropoulou
EGEfstathia Giannopoulou
Efstathia Giannopoulou
MLMichalis Leotsinidis
Michalis Leotsinidis
ITIrine Tsota
Irine Tsota
DKDimitrios Kardamakis
Dimitrios Kardamakis

1 January 2009 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
AKAngelos Koutras
Angelos Koutras
EGEfstathia Giannopoulou
Efstathia Giannopoulou
IKIsmini Kritikou
Ismini Kritikou
AAAnna Antonacopoulou
Anna Antonacopoulou
TETr Jeffry Evans
Tr Jeffry Evans
HKHaralabos Kalofonos
Haralabos Kalofonos
Recent evidence suggests that estrogen signaling may be involved in the pathogenesis of non-small cell lung cancer (NSCLC). Aromatase is an enzyme complex that catalyses the final step in estrogen synthesis and is present in several tissues, including the lung. In the current study we investigated the activity of the aromatase inhibitor exemestane in human NSCLC cell lines H23 and A549.

15 July 2009 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
EGEfstathia Giannopoulou
Efstathia Giannopoulou
KDKonstantinos Dimitropoulos
Konstantinos Dimitropoulos
Andreas A. ArgyriouAndreas A. Argyriou
Andreas A. Argyriou
AKAngelos K. Koutras
Angelos K. Koutras
FDFoteinos-Ioannis Dimitrakopoulos
Foteinos-Ioannis Dimitrakopoulos
HKHaralabos P. Kalofonos
Haralabos P. Kalofonos